#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Diabetes mellitus, hypertension and kidney


Authors: V. Monhart
Authors‘ workplace: Interní klinika 1. lékařské fakulty UK a ÚVN Praha, přednosta prof. MUDr. Miroslav Zavoral, Ph. D.
Published in: Vnitř Lék 2008; 54(5): 499-507
Category:

Předneseno na 9. celostátním diabetologickém sympoziu „Diabetes a urogenitální systém“ ve dnech 1.-2. června 2007 v Novém Adalbertinu v Hradci Králové

Overview

The correlations co-exist among diabetes mellitus, hypertension and the kidney. Renal injury will develop in 35% type-1 and type-2 diabetes mellitus patients. Diabetic nephropathy is the key factor for the occurence of hypertension in type-1 diabetes mellitus. In case of type-2 diabetes mellitus with prevalent essencial hypertension the diabetic nephropathy is supporting factor for the development of hypertension. Untreated or inadequately treated hypertension accelerates the progression of diabetic renal impairment. The presence of diabetes mellitus as well as hypertension or proteinuria is significant cardiovascular risk factor. The goal of treatment with angiotensin converting enzyme inhibitors or AT1 receptor of angiotensin II blockers is both slowing-down of renal injury progression and reduction in risk of cardiovascular complications.

Keywords:
diabetes mellitus - arterial hypertension - diabetic nephropathy - renoprotection - ACE inhibitors - AT1 blockers


Sources

1. Svačina Š. Hypertenze při obezitě a diabetu. Praha: Triton 2007.

2. Cífková R. Léčba hypertenze u pacientů s diabetes mellitus ve světle posledních evropských doporučení. Remedia 2004; 14: 133-141.

3. Škrha J. Arteriální hypertenze u diabetiků v ČR: výsledky studie. In: Widimský J et al. Arteriální hypertenze - současné klinické trendy. V. sympozium - sborník přednášek. Praha: Triton 2007: 43-48.

4. Parving HH. Impact of blood pressure and antihypertensive treatment on incipient and overt nephropathy, retinopathy, and endothelial permeability in diabetes mellitus. Diabetes Care 1991; 14: 260-269.

5. Tesař V. Hypertenze u diabetické nefropatie. In: Rychlík I, Tesař V et al. Onemocnění ledvin u diabetes mellitus. Horizonty diabetologie. Díl 2. Praha: Tigis 2005: 150-161.

6. Rychlík I, Tesař V et al. Onemocnění ledvin u diabetes mellitus. Horizonty diabetologie. Díl 2. Praha: Tigis 2005.

7. De Mast Q, Beutler JJ. Prevalence of atherosclerotic renal artery stenosis: a meta-analysis of 33 studies and 13,591 patients. J Hypertens 2005; 23(Suppl 2): S333.

8. Monhart V. Ischemická nefropatie u diabetiků. In: Rychlík I, Tesař V et al. Onemocnění ledvin u diabetes mellitus. Horizonty diabetologie. Díl 2. Praha: Tigis 2005: 242-254.

9. Dusilová Sulková S, Rychlík I. Přístup nefrologa k diabetikovi s poškozením ledvin. In: Dusilová Sulková S, Šmahelová A. Multidisciplinární přístup k diabetikovi s onemocněním ledvin. Praha: Tigis 2007: 43-52.

10. 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187.

11. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007; 49(Suppl 2): S1-S179.

12. Widimský J jr, Cífková R, Špinar J et al (za Českou společnost pro hypertenzi). Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2007. Doporučení České společnosti pro hypertenzi. Cor et Vasa 2008; 50: K005-K020.

13. Marshall SM. Clinical features and management of diabetic nephropathy. In: Textbook of Diabetes. 3rd ed. Oxford: Blackwell Science 2006: 53.1-53.22.

14. Rušavý Z. Diabetická nefropatie. Akt Nefrol 2002; 8: 77-81.

15. Bakker A. Detection of microalbuminuria. Receiver operating characteristic curve analysis favors albumin-to-creatinine ratio over albumin concentration. Diabetes Care 1999; 22: 307-313.

16. Allen T, Cao Z, Youssef S et al. Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies. Diabetes 1997; 46: 1612-1618.

17. Bakris GL, Weir MR, De Quatro V et al. Effects of an ACE inhibitors/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54: 1283-1289.

18. Perušičová J, Rosolová H, Kvapil M. Mikroalbuminurie. In: Trendy soudobé nefrologie. Praha: Galén 1999: 121-135.

19. Chatuverdi N, Bandinelli S, Mangili R et al. Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int 2001; 60: 219-227.

20. Mogensen CE. How to protect the kidney in diabetic patients: with special reference to IDDM. Diabetes 1997; 46(Suppl 2): S104-S111.

21. UKPDS Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications on patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.

22. Miyata T, van Ypersele de Strihou Ch. Renoprotection of angiotensin receptor blockers: beyond blood pressure lowering. Nephrol Dial Transplant 2006; 21: 846-849.

23. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317: 703-713.

24. Villarosa IP, Bakris GL. Antihypertensive therapy in type 2 diabetes with neprohropathy. In: Ritz E, Rychlík I (eds). Nepropathy in type 2 diabetes. Oxford: Oxford University Press 1999: 111-136.

25. Kasiske BL, Kalil RS, Ma JZ et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118: 129-138.

26. Monhart V. Hypertenze a ledviny. 2nd ed. Praha: Triton 2007.

27. The EUCLID study group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-1792.

28. Viberti G, Mogensen CE, Groop LC et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994; 271: 275-279.

29. Katayama S, Kikkawa R, Isogai S et al. Effect of captopril or imidapril on the progression of diabetic nepropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM). Diab Res Clin Pract 2002; 55: 113-121.

30. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462.

31. Ravid M, Brosh D, Levi Z et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998; 128: 982-988.

32. Ruggenenti P, Fassi A, Parvano Ilieva A et al (for the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT)). Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-1951.

33. Ravid M, Savin H, Jutrin I et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 577-581.

34. Ravid M, Neumann L, Lishner M. Plasma lipids and the progression of nephropathy in diabetes mellitus type II: effect of ACE inhibitors. Kidney Int 1995; 47: 907-910.

35. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.

36. Barnett AH, Bain SC, Bouter P et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952-1961.

37. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan of the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.

38. Viberti G, Wheeldon NM (for the MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators). Microalbuminuria reduction with valsartran in patients with type 2 diabetes mellitus. A blood pressure-independent effect. Circulation 2002; 106: 672-678.

39. Brenner BM, Coper ME, deZeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.

40. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 851-860.

41. Galle J, Quispe Bravo S, Wanner C. Antiproteinuric effects of telmisartan versus valsartan in patients with type 2 diabetes and overt nephropathy. Diabet Med 2006; 23(Suppl 4): 92-93.

42. Burgess E, Bakris G, Weir M et al. Comparative long term effects of two AT1 receptor blockers on proteinuria in patients with type-2 diabetes and overt nephropathy and hypertension: results of the AMADEO trial. J Hypertens 2007; 25(Suppl 2): S276-S277.

43. Mogensen CE, Neldan S, Tikkanen I et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Brit Med J 2000; 321: 1440-1444.

44. Coresh J, Astor BC, Greene T et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41: 1-12.

45. De Zeeuw D, Hillege HL, de Jong PE. The kidney, a cardiovascular risk marker and a new target for therapy. Kidney Int 2005; 68(Suppl 98): 25-29.

46. Wild S, Roglic G, Green A et al. Global prevalence of diabetes: Estimations for the year 2000 and projection for 2030. Diabetes Care 2004; 27: 1047-1053.

47. Kearney PM, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-223.

48. National Kidney Foundation. K/DOQI Clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease: executive summary. Am J Kidney Dis 2004; 43: S14-S33.

Labels
Diabetology Endocrinology Internal medicine
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#